Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nordic Nanovector ASA ( (DE:8NN) ) has issued an update.
Thor Medical ASA is scheduled to release its second half and full-year results for 2024 on February 26, 2025. The results presentation, including a Q&A session, will be available both at Carnegie’s offices in Oslo and through a live webcast, allowing stakeholders to engage directly with the company’s financial announcements.
More about Nordic Nanovector ASA
Thor Medical is an emerging supplier of radionuclides, primarily focusing on alpha particle emitters derived from naturally occurring thorium. Its innovative production process, which requires no irradiation or use of nuclear reactors, offers a reliable, environmentally friendly, and cost-efficient supply for the radiopharmaceutical industry. The company is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: -10.0%
Average Trading Volume: 5,631
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €64.71M
See more data about 8NN stock on TipRanks’ Stock Analysis page.
